Leadership Team

President and CEO: H. Joseph Reiser, Ph.D.

H. Joseph Reiser, Ph.D., has more than 38 years of pharmaceutical and biotech experience in both public and private companies. In large pharma, Dr. Reiser was Corporate Vice President and General Manager, Pharmaceuticals and a member of the Board of Directors for Berlex Laboratories, the U.S. subsidiary of Schering AG (now Bayer AG). During his 17 year tenure at Berlex, Dr. Reiser held numerous senior leadership positions, including President of Schering Berlin’s Venture Corporation, Vice President, Technology and Industry Relations, and Vice President, Drug Development. In the biotech space, Dr. Reiser led or founded 7 biotech companies including 2 NASDAQ-listed public companies, CYTOGEN and Cortendo AB (now StrongBridge) and 5 private companies including Mito Biopharma where he serves as President and CEO and member of the Board.  Dr. Reiser has served on numerous Boards and has served as Board Chairman of three companies, more recently Complexa Inc., a clinical stage platform company focusing on fibrosis and inflammation. Dr. Reiser has also served as Chairman of the New Jersey Biotechnology Council from 2001 to 2002 and concluded a six-year tenure as member of the Board and Executive Committee of the Pennsylvania Biotech Association. Dr. Reiser received his Masters and Ph.D. in Physiology from Indiana University School of Medicine and earned a  Bachelor of Science degree from Indiana University.  Dr. Reiser has  served on the Mito Pharma Board since 2015.

Founder and Acting CSO: Victor Jin, Ph.D.

Victor Shengkan Jin, Ph.D. is an Associate Professor of Pharmacology at Robert Wood Johnson Medical School of UMDNJ. He also holds joint faculty memberships at the Center for Lipid Research at Rutgers University, the Cardiovascular Institute of New Jersey, and the Cancer Institute of New Jersey. Before joining the faculty of UMDNJ in 2003, Dr. Jin received B.S. in Biological Sciences at Tsinghua University in 1992, received a Ph.D. in Pharmacology and Experimental Therapeutics at Cornell University Weill Medical College/Memorial Sloan Kettering Cancer Center in 1999, and completed postdoctoral training at Rockefeller University in 2002. His research at UMDNJ has been funded by major grants from the National Institute on Aging (NIH/NIA), National Cancer Institute (NIH/NCI), Department of Defense (DOD), and American Cancer Society (ACS).   He has served on many scientific review panels, including NIH and  American Cancer Society. Dr. Jin is an internationally recognized expert on research in metabolism and cancer. Dr. Jin is the founder of Mito Biopharma LLC.

Director of Molecular Design and Synthesis: David J Augeri, Ph.D.
Medicinal Chemistry Synthesis: Bin Cao, Ph.D.
Biological Screen and Efficacy Testing: Hanlin Tao, Ph.D.